<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01319760</url>
  </required_header>
  <id_info>
    <org_study_id>MINI-AMI G100286</org_study_id>
    <nct_id>NCT01319760</nct_id>
  </id_info>
  <brief_title>MINI-AMI: Minimizing Infarct Size With Impella 2.5 Following PCI for Acute Myocardial Infarction</brief_title>
  <acronym>MINI-AMI</acronym>
  <official_title>MINI-AMI: Minimizing INfarct Size With IMPELLA® 2.5 System Following PCI for Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abiomed Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abiomed Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, randomized, controlled multi-site feasibility trial to assess the potential
      role of the IMPELLA® 2.5 System in reducing infarct size in patients with ST-elevation
      myocardial infarction (STEMI)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to evaluate whether the adjunctive use of the IMPELLA®
      2.5 System for 24 hours following primary PCI for STEMI has the potential to limit the
      infarction of at-risk myocardium compared to primary PCI with routine post-PCI care (standard
      of care). This study is a feasibility study. Therefore, the principal objective is to
      identify trends in cardiac magnetic resonance imaging (MRI)-based efficacy outcomes between
      the randomized treatment arms (Impella arm compared standard of care.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Change in business priority
  </why_stopped>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Infarct Size</measure>
    <time_frame>3-5 Days post infarct</time_frame>
    <description>Infarct size (as assessed by cardiac MRI at 3-5 days following the infarction).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>No Data for Primary or Secondary Enpoints Were Collected</measure>
    <time_frame>No data for primary or secondary enpoints were collected</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Infarct Size</measure>
    <time_frame>90 Days</time_frame>
    <description>Assessment of infarct size and remodeling characteristics at 90 days post-infarct.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>ST-elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients in the control arm will be treated with standard of care for post-PCI STEMI patients in accordance with the the 2004 ACC/AHA Guidelines for the Management of Patients with ST-elevation Myocardial Infarction.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Impella 2.5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 hours of support with the Impella 2.5 post-PCI for acute myocardial infarction.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Impella 2.5 support</intervention_name>
    <description>Patients enrolled in the Impella arm will receive 24 hours of post-PCI hemodynamic support using the Impella 2.5</description>
    <arm_group_label>Impella 2.5</arm_group_label>
    <other_name>Impella LP 2.5</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of care (Control)</intervention_name>
    <description>Standard care for STEMI patients post-PCI from ACC/AHA Guidelines</description>
    <arm_group_label>Standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Signed Informed Consent

          -  Acute anterior STEMI with ≥2 mm of ST-segment elevation in 2 or more contiguous
             anterior leads or ≥ 4 mm in total in the anterior leads, OR, Large Inferior STEMI with
             ≥2 mm of ST-segment elevation in 2 or more inferior leads AND EITHER ≥1 mm ST-segment
             elevation in V1 OR ≥1 mm of ST-segment depression in ≥2 contiguous anterior leads
             (V1-V3)

          -  Primary PCI performed within 5 hours of the onset of symptoms

          -  Patient undergoing emergent primary PCI of one culprit lesion in one major native
             epicardial coronary vessel

          -  Successful revascularization of the culprit native coronary artery with TIMI Flow
             Grade of 3 at the end of PCI

        Exclusion Criteria:

          -  Cardiac arrest requiring CPR within 24 hours prior to enrollment

          -  Current cardiogenic shock

          -  Left Bundle Branch Block (new or old)

          -  Atrial fibrillation

          -  Known history of prior MI

          -  Prior coronary artery bypass graft surgery

          -  Known mural thrombus in the left ventricle or contraindication to left
             ventriculography

          -  Presence of a mechanical aortic valve

          -  Documented presence of moderate to severe aortic stenosis or moderate to severe aortic
             insufficiency.

          -  Known history of severe kidney dysfunction.

          -  Known contraindication to MRI (implanted metallic or magnetically activated device;
             claustrophobia, inability to hold breath for 15 seconds).

          -  History of recent (within 1 month) stroke or TIA

          -  History of bleeding diathesis or known coagulopathy (including heparin-induced
             thrombocytopenia), or will refuse blood transfusions.

          -  Administration of fibrinolytic therapy within 24 hours

          -  Known hypersensitivity or contraindication to any of the following: Heparin, pork or
             pork products; Aspirin, All of the following: Clopidogrel, Ticlopidine, Prasugrel

          -  Contrast media Participation in the active treatment or follow-up phase of another
             clinical study of an investigational drug or device.

          -  Severe peripheral arterial obstructive disease that would preclude the IMPELLA® System
             placement

          -  Requirement to treat two or more culprit vessels during primary PCI, or plan for
             staged coronary revascularization (PCI or CABG) within the next 30 days.

          -  Inability to place Impella within 6 hours of the onset of symptoms, should patient be
             randomized to this arm.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Moses, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia Presbyterian</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ajay Kirtane, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia Presbyterian</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>March 18, 2011</study_first_submitted>
  <study_first_submitted_qc>March 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2011</study_first_posted>
  <results_first_submitted>July 29, 2016</results_first_submitted>
  <results_first_submitted_qc>April 29, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 13, 2019</results_first_posted>
  <last_update_submitted>April 29, 2019</last_update_submitted>
  <last_update_submitted_qc>April 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>STEMI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Five roll-in subjects were enrolled in the MINI-AMI feasibility study between September 14, 2011 and April 24, 2012. A total of 82 patients have been screened but not enrolled by participating sites during the study period. Five (5) sites participated in the MINI-AMI study.</recruitment_details>
      <pre_assignment_details>The study experienced a very low enrollment rate (lower than expected). The study was terminated before the roll-in phase was completed. No data for primary or secondary endpoints were collected in this study</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Control (Standard of Care PCI Without Using Impella)</title>
          <description>Patients in the control arm will be treated with standard of care for postPCI STEMI patients in accordance with the 2004 ACC/AHA Guidelines for the Management of Patients with STelevation Myocardia Infarction</description>
        </group>
        <group group_id="P2">
          <title>Experimental (PCI Preceded With Impella 2.5)</title>
          <description>Patients in this arm will be treated in accordance with standard of care, and in addition will receive 24 hours of support with the Impella 2.5 postPCI for acute myocardial infarction.
Impella 2.5 support: Patients enrolled in the Impella arm will receive 24 hours of postPCI hemodynamic support using the Impella 2.5.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">The study experienced a very low enrollment rate. the sponsor decided to stop the study.</participants>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">The study experienced a very low enrollment rate. the sponsor decided to stop the study.</participants>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Only three (3) sites enrolled in the roll in phase. A total of five (5) patients were enrolled before the study was closed out. Investigators at each site were asked to enroll two initial roll-in patients that will be treated with the IMPELLA® 2.5 System.These roll in patients were not to be part of the primary analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>Control</title>
          <description>Patients in the control arm will be treated with standard of care for post-PCI STEMI patients in accordance with the the 2004 ACC/AHA Guidelines for the Management of Patients with ST-elevation Myocardial Infarction.
Control: Standard care for STEMI patients post-PCI from ACC/AHA Guidelines</description>
        </group>
        <group group_id="B2">
          <title>Impella 2.5</title>
          <description>Patients in this arm will be treated in accordance with standard of care, and in addition will receive 24 hours of support with the Impella 2.5 post-PCI for acute myocardial infarction.
Impella 2.5 support: Patients enrolled in the Impella arm will receive 24 hours of post-PCI hemodynamic support using the Impella 2.5</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="61.8" spread="10.9"/>
                    <measurement group_id="B3" value="61.8" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Infarct Size</title>
        <description>Infarct size (as assessed by cardiac MRI at 3-5 days following the infarction).</description>
        <time_frame>3-5 Days post infarct</time_frame>
        <population>No data for primary or secondary endpoints were collected in this study</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
          </group>
        </group_list>
        <measure>
          <title>Infarct Size</title>
          <description>Infarct size (as assessed by cardiac MRI at 3-5 days following the infarction).</description>
          <population>No data for primary or secondary endpoints were collected in this study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>No Data for Primary or Secondary Enpoints Were Collected</title>
        <time_frame>No data for primary or secondary enpoints were collected</time_frame>
        <population>No data from primary or secondary endpoints were collected in this study</population>
        <group_list>
          <group group_id="O1">
            <title>Roll In</title>
            <description>Infarct size</description>
          </group>
        </group_list>
        <measure>
          <title>No Data for Primary or Secondary Enpoints Were Collected</title>
          <population>No data from primary or secondary endpoints were collected in this study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Infarct Size</title>
        <description>Assessment of infarct size and remodeling characteristics at 90 days post-infarct.</description>
        <time_frame>90 Days</time_frame>
        <population>No data for primary or secondary endpoints were collected in this study</population>
        <group_list>
          <group group_id="O1">
            <title>Roll in</title>
            <description>Study close in roll in phase. therefore, no comparison data available.</description>
          </group>
        </group_list>
        <measure>
          <title>Infarct Size</title>
          <description>Assessment of infarct size and remodeling characteristics at 90 days post-infarct.</description>
          <population>No data for primary or secondary endpoints were collected in this study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>90 days</time_frame>
      <desc>Study close in roll in phase. Therefore, no comparison data available.</desc>
      <group_list>
        <group group_id="E1">
          <title>Roll In</title>
          <description>Study close in roll in phase. Therefore, no comparison data available.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Decrease in Hemolobin</sub_title>
                <description>Bleeding</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <description>Mortality (Cardiovascular and Non-cardiovascular)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute renal dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiogenic Shock</sub_title>
                <description>Vascular complications(sub-categorized as either Major or Minor)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hemolysis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Significant platelet dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Worsening heart failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Renal Dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study close in roll in phase. Therefore, no comparison data available.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Ajay Kirtane</name_or_title>
      <organization>Columbia Presbytarian Hospital, NY</organization>
      <phone>212-305-7060</phone>
      <email>akirtane@columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

